...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical psychiatry >An 8-week open-label trial of a 6-day course of mifepristone for the treatment of psychotic depression.
【24h】

An 8-week open-label trial of a 6-day course of mifepristone for the treatment of psychotic depression.

机译：米非司酮治疗精神病性抑郁症的为期6天疗程的8周开放标签试验。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: Several investigations suggest that mifepristone leads to the rapid amelioration of psychotic depression. However, these studies were of short duration (1 week or less) and included subjects who were taking other psychotropic medications. The goals of this study were to extend these findings by conducting an 8-week trial of mifepristone for subjects with psychotic depression who were taking no concomitant psychiatric medications. METHOD: Twenty subjects with a DSM-IV major depressive episode with psychotic features (for convenience we use the term psychotic depression) taking no psychotropic medications were given a 6-day course of mifepristone and followed as inpatients for a total of 8 weeks. Nonblinded ratings using the Hamilton Rating Scale for Depression (HAM-D) and Clinical Global Impressions scale (CGI) were performed at baseline and at the end of weeks 1, 4, and 8. The Brief Psychiatric Rating Scale (BPRS) was also administered at baseline and after weeks 4 and 8. Subjects were recruited between February 2003 and December 2003. RESULTS: Significant improvements in HAM-D and CGI scores were shown after 1 week and between weeks 1 and 4 but not between weeks 4 and 8. BPRS scores improved significantly after week 4, while the improvement in BPRS scores between weeks 4 and 8 was of borderline significance. CONCLUSION: Mifepristone appears to be a useful intervention for psychotic depression, leading to significant improvements even after a 1-week course of administration. Issues related to its optimal dosing and to prediction of response are discussed, as are the implications of lack of a placebo group and the use of nonblinded ratings in the present study.
机译：目的：多项研究表明，米非司酮可导致精神病性抑郁症的快速缓解。但是，这些研究持续时间短（1周或更短），并且包括正在服用其他精神药物的受试者。这项研究的目的是通过对未服用精神科药物的精神病性抑郁症患者进行为期8周的米非司酮试验来扩展这些发现。方法：20名患有精神病特征的DSM-IV重度抑郁发作的受试者（为方便起见，我们使用精神病抑郁）未服用精神药物的患者接受了6天的米非司酮疗程，并作为住院病人，共住院8周。使用汉密尔顿抑郁量表（HAM-D）和临床总体印象量表（CGI）在基线时以及第1、4和8周结束时进行非盲人评分。还使用了简要精神病学量表（BPRS）在基线以及第4周和第8周之后。在2003年2月至2003年12月之间招募了受试者。结果：HAM-D和CGI评分显着改善，显示在1周后，第1周和第4周之间，但在第4周和第8周之间。在第4周后，评分明显改善，而在第4周和第8周之间，BPRS评分的改善具有临界意义。结论：米非司酮似乎是一种治疗精神病性抑郁症的有效干预措施，即使在给药1周后仍可带来显着改善。讨论了与最佳剂量和反应预测有关的问题，以及缺乏安慰剂组和在本研究中使用非盲目评分的含义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号